https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-the-40th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-plan-for-a-resubmission-of-its-supplemental-new-drug
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-promotion-of-mark-schneyer-to-executive-vice
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-positive-top-line-results-from-the-pivotal-phase-3
https://www.nasdaq.com/press-release/the-lancet-psychiatry-publishes-results-from-advance-study-evaluating-pimavanserin
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-and-storycorps-collaborate-to-launch-yours-truly-a
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-reports-third-quarter-2021-financial-results-2021-11-08
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-presents-new-dementia-related-psychosis-real-world-outcomes
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-appoints-brendan-teehan-executive-vice-president-chief
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-announce-third-quarter-2021-financial-results-on-november-8
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-data-on-pimavanserin-in-patients-with-parkinsons
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-upcoming-investor-conferences-2021-09-02
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-executive-leadership-change-2021-09-01
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-the-canaccord-genuity-41st-annual-growth
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-reports-second-quarter-2021-financial-results-2021-08-04
https://www.nasdaq.com/press-release/the-new-england-journal-of-medicine-publishes-results-from-the-phase-3-harmony-study
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-announce-second-quarter-2021-financial-results-on-august-4
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-new-scientific-data-on-pimavanserin-in-0
https://www.nasdaq.com/press-release/nuplazidr-pimavanserin-efficacy-data-from-open-label-extension-ole-study-published-in
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-upcoming-investor-conferences-2021-05-26
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-reports-first-quarter-2021-financial-results-2021-05-05
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-upcoming-investor-conferences-2021-05-04
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-announce-first-quarter-2021-financial-results-on-may-5-2021
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-receives-complete-response-letter-from-u.s.-fda-for
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-provides-regulatory-update-on-supplemental-new-drug
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-recognizes-national-caregivers-day-with-launch-of
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-upcoming-investor-conferences-2021-02-18
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2020-financial
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-commercial-leadership-change-2021-01-27
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-the-39th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-the-stifel-2020-virtual-healthcare-conference-on
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-reports-third-quarter-2020-financial-results-2020-11-04
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-new-scientific-data-on-pimavanserin-in
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-announce-third-quarter-2020-financial-results-on-november-4
https://www.nasdaq.com/press-release/the-lewy-body-dementia-association-and-acadia-pharmaceuticals-to-release-educational
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-appoints-elizabeth-garofalo-m.d.-to-board-of-directors-2020-10
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-upcoming-investor-conferences-2020-09-02
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-appoints-gudarz-davar-m.d.-as-executive-vice-president-and
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-acquires-cersci-therapeutics-adds-novel-pain-program-to
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-the-jmp-securities-cns-forum-on-august-19-2020
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-reports-second-quarter-2020-financial-results-2020-08-05
https://www.nasdaq.com/press-release/people-with-dementia-and-caregivers-share-the-significant-burden-of-visual
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-announce-second-quarter-2020-financial-results-on-august-5
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-u.s.-fda-accepted-for-filing-the-supplemental-new
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-top-line-results-from-the-phase-3-clarity-study
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-submits-supplemental-new-drug-application-to-u.s.-fda-for
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-the-goldman-sachs-41st-annual-global-healthcare
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-appoints-mark-schneyer-as-senior-vice-president-business
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-combine-clarity-2-and-clarity-3-phase-3-studies-evaluating
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-pimavanserin-clinical-data-at-the-2020-american
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-reports-first-quarter-2020-financial-results-2020-05-07
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-and-vanderbilt-university-announce-exclusive-license-agreement
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-two-upcoming-virtual-investor-conferences-2020
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-announce-first-quarter-2020-financial-results-on-may-7-2020
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-and-neuren-pharmaceuticals-announce-rare-pediatric-disease
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-the-cowen-and-company-40th-annual-health-care
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2019-financial
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-the-38th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-appoints-stephanie-fagan-as-senior-vice-president-corporate
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-presents-positive-top-line-results-from-pivotal-phase-3
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-positive-top-line-results-from-advance-trial-of
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-host-investor-event-and-webcast-from-clinical-trials-on
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-appoints-ponni-subbiah-m.d.-m.p.h.-as-senior-vice-president
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-initiates-phase-3-pivotal-study-of-trofinetide-in-rett
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-reports-third-quarter-2019-financial-results-2019-10-30
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-announce-third-quarter-2019-financial-results-on-october-30
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-presents-additional-positive-data-from-the-phase-2-clarity
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-late-breaking-oral-presentation-of-the-phase-3
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-at-the-2019-cantor-global-healthcare-conference-on
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-that-the-journal-of-clinical-psychiatry-publishes
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-presents-new-data-on-pd-patients-treated-with-pimavanserin-for
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-full
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-to-present-new-clinical-data-and-outcomes-research-at-upcoming
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-prices-public-offering-of-common-stock-2019-09-17
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-proposed-public-offering-of-common-stock-2019-09-17
https://www.nasdaq.com/press-release/thinking-about-buying-stock-in-acadia-pharmaceuticals-aurora-cannabis-bank-of-america
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-announces-pivotal-phase-3-harmony-trial-stopped-early-for
https://www.nasdaq.com/press-release/acadia-pharmaceuticals-reports-second-quarter-2019-financial-results-2019-09-18
